Campath and renal transplant rejection

Clinical Transplantation

Volumn 18, Issue 6, 2004, Pages 759-761

  Thomas, Philip G ^a   Ishihara, Kanae ^b   Vaidya, Smita ^a   Gugliuzza, Kristene K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Campath; Renal rejection; Vascular rejection

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; CALCINEURIN; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG RESPONSE; ENZYME DEFECT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MEDICAL DOCUMENTATION; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; TOXICITY; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE;

EID: 8644268248     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00288.x     Document Type: Article

References (7)

1. Friend PJ, Hale G, Waldmann H et al. Campath-1M-prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation 1989: 48: 248.
2. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998: 351: 1701.
3. Friend PJ, Waldmann H, Hale G et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc 1991: 23: 2253.
4. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003: 76: 120.
5. Reams BD, Davis RD, Curl J, Palmer SM. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. Transplantation 2002: 74: 903.
6. Potdar S, Shapiro R, Thai N et al. Successful reversal of refractory acute rejection with Campath 1H in pancreas transplant. American Transplant Congress 2003: Abstract no. 670.
7. Carreno MR, Ciancio G, Burke GW et al. Cellular phenotypes affected by induction therapy with Campath 1-H vs. thymoglobulin vs. zenapax in kidney allograft recipients. American Transplant Congress 2004, Boston, MA: Abstract no. 904.